Cytosorbents CorpCTSOEarnings & Financial Report
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
Revenue
$8.7M
Gross Profit
$6.2M
Operating Profit
$-3.9M
Net Profit
$-1.5M
Gross Margin
71.1%
Operating Margin
-44.5%
Net Margin
-16.9%
YoY Growth
-2.9%
EPS
$-0.02
Cytosorbents Corp Q1 FY2025 Financial Summary
Cytosorbents Corp reported revenue of $8.7M (down 2.9% YoY) for Q1 FY2025, with a net profit of $-1.5M (up 75.7% YoY) (-16.9% margin). Cost of goods sold was $2.5M, operating expenses totaled $10.1M.
Key Financial Metrics
| Total Revenue | $8.7M |
|---|---|
| Net Profit | $-1.5M |
| Gross Margin | 71.1% |
| Operating Margin | -44.5% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
Cytosorbents Corp Q1 FY2025 revenue of $8.7M breaks down across 2 segments, led by Direct at $4.7M (54.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Direct | $4.7M | 54.4% |
| Distributors And Strategic Partners | $4.0M | 45.6% |
Cytosorbents Corp Revenue by Segment — Quarterly Trend
Cytosorbents Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Direct and Distributors And Strategic Partners) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Direct | $5.1M | $5.2M | $5.6M | $4.7M |
| Distributors And Strategic Partners | $4.2M | $4.3M | $4.0M | $4.0M |
Cytosorbents Corp Annual Revenue by Year
Cytosorbents Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $37.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $37.1M |
| 2024 | $35.6M |
| 2023 | $31.1M |
| 2022 | $34.7M |
Cytosorbents Corp Quarterly Revenue & Net Profit History
Cytosorbents Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $9.2M | +0.9% | $-5.5M | -59.5% |
| Q3 FY2025 | $9.5M | +10.1% | $-3.2M | -33.4% |
| Q2 FY2025 | $9.6M | +8.8% | $1.9M | 20.2% |
| Q1 FY2025 | $8.7M | -2.9% | $-1.5M | -16.9% |
| Q4 FY2024 | $9.2M | +168.8% | $-7.6M | -82.7% |
| Q3 FY2024 | $8.6M | -2.2% | $-2.8M | -32.1% |
| Q2 FY2024 | $8.8M | -6.1% | $-4.3M | -48.6% |
| Q1 FY2024 | $9.0M | -4.9% | $-6.1M | -67.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $8.8M | $8.6M | $9.2M | $8.7M | $9.6M | $9.5M | $9.2M |
| YoY Growth | -4.9% | -6.1% | -2.2% | 168.8% | -2.9% | 8.8% | 10.1% | 0.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $47.1M | $53.4M | $47.8M | $47.4M | $50.8M | $48.0M | $45.8M | $44.2M |
| Liabilities | $27.4M | $36.0M | $34.7M | $36.3M | $36.2M | $36.4M | $36.7M | $38.3M |
| Equity | $19.6M | $17.4M | $13.4M | $11.1M | $14.5M | $11.6M | $9.0M | $5.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.8M | $-4.8M | $-2.5M | $-2.3M | $-3.5M | $-1.5M | $-2.6M | $-4.8M |